Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis
暂无分享,去创建一个
Y. Hiasa | A. Morishita | J. Tani | T. Ishikawa | Shinichiro Nakamura | K. Nouso | H. Toyoda | K. Tajiri | H. Iijima | S. Kakizaki | T. Kumada | M. Hirooka | A. Hiraoka | H. Ochi | K. Joko | Y. Koizumi | S. Fukunishi | T. Tada | S. Yasuda | A. Naganuma | K. Takaguchi | N. Shimada | M. Atsukawa | K. Kariyama | H. Ohama | N. Itokawa | Chikara Ogawa | T. Okubo | Taeang Arai | T. Nishimura | K. Tsuji | E. Itobayashi | A. Tsutsui | K. Kawata | T. Hatanaka | M. Imai | Takaaki Tanaka | T. Nagano | C. Ogawa | T. Arai
[1] J. Ferlay,et al. Cancer statistics for the year 2020: An overview , 2021, International journal of cancer.
[2] J. Llovet,et al. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] A. Zhu,et al. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Yulei N. Wang,et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. , 2020, The Lancet. Oncology.
[5] J. Marrero,et al. Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference , 2020, Hepatology.
[6] Yulei N. Wang,et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.
[7] M. Kudo,et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.
[8] Gisela Schwab,et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma , 2018, The New England journal of medicine.
[9] M. Kudo,et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.
[10] M. Abecassis,et al. AASLD guidelines for the treatment of hepatocellular carcinoma , 2018, Hepatology.
[11] P. Hegde,et al. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. , 2017, Seminars in cancer biology.
[12] M. Kudo,et al. Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function , 2017, Liver Cancer.
[13] Masatoshi Kudo,et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.
[14] Suzanne F. Jones,et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma , 2016, Nature Communications.
[15] B. Sangro,et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] E. Tartour,et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors , 2015, The Journal of experimental medicine.
[17] Y. Kanda,et al. Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.
[18] J. Pignon,et al. Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. , 2012, The oncologist.
[19] Srinivas Nagaraj,et al. Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.
[20] S. Paggi,et al. Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.
[21] S. Rafii,et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] D. Carbone,et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. , 1998, Journal of immunology.
[23] P. Hansell,et al. Leukocyte adhesion in angiogenic blood vessels. Role of E-selectin, P-selectin, and beta2 integrin in lymphotoxin-mediated leukocyte recruitment in tumor microvessels. , 1997, The Journal of clinical investigation.
[24] D. Carbone,et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells , 1996, Nature Medicine.
[25] Yoon-Koo Kang,et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.
[26] D. Woodfield. Hepatocellular carcinoma. , 1986, The New Zealand medical journal.